Publications

PEER REVIEWED ARTICLES FROM HBM4EU

1 - Concentrations of perfluoroalkyl substances in donor breast milk in Southern Spain and their potential determinants
Serrano L, Iribarne-Durán LM, Suárez B, Artacho-Cordón F, Vela-Soria F, Peña- Caballero M, Hurtado JA, Olea N, Fernández MF, Freire C 06/2021
2 - Urinary metabolites of non-persistent pesticides and serum hormones in Spanish adolescent males.
Freire C, Suárez B, Vela-Soria F, Castiello F, Reina-Pérez I, Andersen HR, Olea N, Fernández MF 03/2021
3 - HBM4EU combines and harmonises human biomonitoring data across the EU, building on existing capacity – The HBM4EU survey
Liese Gilles, Eva Govarts, Loïc Rambaud, Nina Vogel, Argelia Castaño, Marta Esteban López, Laura Rodriguez Martin, Gudrun Koppen, Sylvie Remy, Martine Vrijheid, Parisa Montazeri, Laura Birks, Ovnair Sepai, Lorraine Stewart, Ulrike Fiddicke, Ilse Loots, Lisbeth E. Knudsen, Marike Kolossa-Gehring, Greet Schoeters 08/2021
4 - Reproductive Health Risks Associated with Occupational and Environmental Exposure to Pesticides
Aleksandra Fucic, Radu C. Duca, Karen S. Galea, Tihana Maric, Kelly Garcia, Michael S. Bloom, Helle R. Andersen and John E. Vena 06/2021
5 - Chemical prioritisation strategy in the European Human Biomonitoring Initiative (HBM4EU) – Development and results
Eva Ougier, Catherine Ganzleben, Pierre Lecoq, Jos Bessems, Madlen David, Greet Schoeters, Rosa Lange, Matthieu Meslin, Maria Uhl, Marike Kolossa-Gehring, Christophe Rousselle, Joana Lobo Vicente 06/2021
6 - Human biomonitoring initiative (HBM4EU): Human biomonitoring guidance values (HBM-GVs) derived for bisphenol A
Eva Ougier, Florence Zeman, Jean-Philippe Antignac, Christophe Rousselle, Rosa Lange, Marike Kolossa-Gehring, Petra Apel 04/2021
7 - The European human biomonitoring platform - Design and implementation of a laboratory quality assurance/quality control (QA/QC) programme for selected priority chemicals
Marta Esteban López, Thomas Göen, Hans Mol, Stefanie Nübler, Karin Haji-Abbas-Zarrabi, Holger M. Koch, Monika Kasper-Sonnenberg, Darina Dvorakova, Jana Hajslova, Jean-Philippe Antignac, Vincent Vaccher, Ingrid Elbers, CathrineThomsen, Katrin Vorkamp, Susana Pedraza – Díaz, Marike Kolossa-Gehring, Argelia Castaño 04/2021
8 - Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
Styliani Fragki, Hubert Dirven,Tony Fletcher, Bettina Grasl-Kraupp, Kristine Bjerve Gützkow, Ron Hoogenboom, Sander Kersten, Birgitte Lindeman, Jochem Louisse, Ad Peijnenburg, Aldert H. Piersma, Hans M. G. Princen, Maria Uhl, Joost Westerhout, Marco J. Zeilmaker & Mirjam Luijten 04/2021
9 - Endocrine disrupting potential of replacement flame retardants – review of current knowledge for nuclear receptors associated with reproductive outcomes
Lola Bajard, Chander K. Negi, Vicente Mustieles, Lisa Melymuk, Stéphane Jomini, Johanna Barthelemy-Berneron, Mariana F. Fernandez, Ludek Blaha 04/2021
10 - A Suspect Screening Database for Chemicals of Emerging Concern in Exposome Research.
Meijer J, Lamoree M, Hamers T, Antignac JP, Hutinet S, Debrauwer L, Covaci A, Huber C, Krauss M, Walker DI, Schymanski EL, Vermeulen R, Vlaanderen J. 03/2021
11 - Biomarkers of effect as determined in human biomonitoring studies on hexavalent chromium and cadmium in the period 2008-2020
Célia Ventura, Bruno Costa Gomes, Axel Oberemm, Henriqueta Louro, Pasi Huuskonen, Vicente Mustieles, Mariana F. Fernández, Sophie Ndaw, Marcel Mengelers, Mirjam Luijten, Claudia Gundacker, Maria João Silva 03/2021
12 - The European Human Biomonitoring Initiative (HBM4EU): Human biomonitoring guidance values for selected phthalates and a substitute plasticizer
Rosa Lange, Petra Apel, Christophe Rousselle, Sandrine Charles, Fatoumata Sissoko, Marike Kolossa-Gehring, Eva Ougier 03/2021
13 - Chemical Exposure: European Citizens’ Perspectives, Trust, and Concerns on Human Biomonitoring Initiatives, Information Needs, and Scientific Results
Maria Uhl, Ricardo R. Santos, Joana Costa, Osvaldo Santos, Ana Virgolino, David S. Evans, Cora Murray, Maurice Mulcahy, Dorothy Ubong, Ovnair Sepai, Joana Lobo Vicente, Michaela Leitner, Silvia Benda-Kahri and Daniela Zanini-Freitag 02/2021
14 - Scoping review – the association between asthma and environmental chemicals
Tiina Mattila, Tiina Santonen, Helle Raun Andersen, Andromachi Katsonouri, Tamás Szigeti, Maria Uhl, Wojciech Wąsowicz, Rosa Lange, Beatrice Bocca, Flavia Ruggieri, Marike Kolossa-Gehring, Denis A. Sarigiannis and Hanna Tolonen 02/2021
15 - Towards harmonised criteria in quality assurance and quality control of suspect and non-target LC-HRMS analytical workflows for screening of emerging contaminants in human biomonitoring
Noelia Caballero-Casero, Lidia Belova, Philippe Vervliet, Jean-Philippe Antignac, Argelia Castaño, Laurent Debrauwer, Marta Esteban López, Carolin Huber, Jana Klanova, Martin Krauss, Arjen Lommen, Hans G.J. Mol, Herbert Oberacher, Olga Pardo, Elliott J. Price, Vera Reinstadler, Chiara Maria Vitale, Alexander L.N. van Nuijs, Adrian Covaci 01/2021
16 - Environmental Substances Associated with Osteoporosis–A Scoping Review
Hanna Elonheimo, Rosa Lange, Hanna Tolonen and Marike Kolossa-Gehring 01/2021
17 - Assessment of chemical mixtures using biomarkers of combined biological activity: A screening study in human placentas
Andrea Rodríguez-Carrillo, Anna Kjerstine Rosenmai, Vicente Mustieles, Stephan Couderq, Jean-Baptiste Fini, Fernando Vela-Soria, Jose Manuel Molina-Molina, Patricia Ferrando-Marco, Eva Cecilie Bonefeld-Jorgensen, Nicolás Olea, Anne Marie Vinggaard, Mariana F. Fernández 01/2021
18 - Human biomonitoring initiative (HBM4EU): Human biomonitoring guidance values (HBM-GVs) derived for cadmium and its compounds
Farida Lamkarkach, Eva Ougier, Robert Garnier, Claude Viau, Marike Kolossa-Gehring, Rosa Lange, Petra Apel 12/2020
19 - A Phased Approach for preparation and organization of human biomonitoring studies
Ulrike Fiddicke, L. Kim Pack, Hanna Tolonen, Ovnair Sepai, Marta Esteban López, Argelia Castaño, Greet Schoeters, Marike Kolossa-Gehring 12/2020
20 - Non-targeted screening methodology to characterise human internal chemical exposure: application to halogenated compounds in human milk.
Pourchet M, Narduzzi L, Jean A, Guiffard I, Bichon E, Cariou R, Guitton Y, Hutinet S, Vlaanderen J, Meijer J, Le Bizec B, Antignac JP. 12/2020
21 - Biomarkers, matrices and analytical methods targeting human exposure to chemicals selected for a European human biomonitoring initiative
Katrin Vorkamp, Argelia Castaño, Jean-Philippe Antignac, Luis D. Boadad, Enrique Cequiere, Adrian Covaci, Marta Esteban López, Line S. Haug, Monika Kasper-Sonnenberg, Holger M. Koch, Octavio Pérez Luzardo, Agnese Osīte, Loïc Rambaud, Maria-Teresa Pinorini, Gabriele Sabbioni, Cathrine Thomsen 11/2020
22 - Exposure to Perflouroalkyl acids and foetal and maternal thyroid status: a review
Sophie A. H. Boesen, Manhai Long, Maria Wielsøe, Vicente Mustieles, Mariana F. Fernandez, Eva C. Bonefeld-Jørgensen 10/2020
23 - Receptor-based in vitro activities to assess human exposure to chemical mixtures and related health impacts
Anne Marie Vinggaard, Eva Cecilie Bonefeld-Jørgensen, Tina Kold Jensen, Mariana F. Fernandez, Anna Kjerstine Rosenmai, Camilla Taxvig, Andrea Rodriguez-Carrillo, Maria Wielsøe, Manhai Long, Nicolas Olea, Jean-Philippe Antignac, Timo Hamers, Marja Lamoree 10/2020
24 - Learning from previous work and finding synergies in the domains of public and environmental health: EU-funded projects BRIDGE Health and HBM4EU
Madlen David, Gerda Schwedler, Lena Reiber, Hanna Tolonen, Anna-Maria Andersson, Marta Esteban López, Anke Joas, Miriam Schöpel, Alexandra Polcher, Marike Kolossa-Gehring 09/2020
25 - Human biomonitoring initiative (HBM4EU) - Strategy to derive human biomonitoring guidance values (HBM-GVs) for health risk assessment
Petra Apel, Christophe Rousselle, Rosa Lange, Fatoumata Sissoko, Marike Kolossa-Gehring, Eva Ougier 09/2020
26 - Bisphenol A and its analogues: A comprehensive review to identify and prioritize effect biomarkers for human biomonitoring
Vicente Mustieles, Shereen Cynthia D'Cruz, Stephan Couderq, Andrea Rodríguez-Carrillo, Jean-Baptiste Fini, Tim Hofer, Inger-Lise Steffensen, Hubert Dirven, Robert Barouki, Nicolás Olea, Mariana F. Fernández, Arthur David 08/2020
27 - Assessment of perfluoroalkyl substances in placenta by coupling salt assisted liquid-liquid extraction with dispersive liquid-liquid microextraction prior to liquid chromatography-tandem mass spectrometry
F.Vela-Soria, J.García-Villanova, V.Mustieles, T.de Haro, J.P.Antignac, M.F.Fernandez 08/2020
28 - Biomonitoring of occupational exposure to phthalates: A systematic review
Nadine Fréry, Tiina Santonen, Simo P. Porras, Aleksandra Fucic, Veruscka Leso, Radia Bousoumah, Radu Corneliu Duca, Mounia El Yamani, Marike Kolossa-Gehring, Sophie Ndaw, Susana Viegas, Ivo Iavicoli 07/2020
29 - Bisphenols and oxidative stress biomarkers – Associations found in human studies, evaluation of methods used, and strengths and weaknesses of the biomarkers
Inger-Lise Steffensen, Hubert Dirven, Stephan Couderq, Arthur David, Shereen Cynthia D'Cruz, Mariana F. Fernández, Vicente Mustieles, Andrea Rodríguez-Carillo, Tim Hofer 05/2020
30 - Biomonitoring of co-exposure to bisphenols by consumers of canned foodstuffs
Neus González, Montse Marquès, Sara C. Cunha, José O. Fernandes, José L. Domingo, Martí Nadal 05/2020
31 - Suspect and non-targeted screening of chemicals of emerging concern for human biomonitoring, environmental health studies and support to risk assessment: From promises to challenges and harmonisation issues
Marianne Pourchet, Laurent Debrauwer, Jana Klanova, Elliott J. Price, Adrian Covaci, Noelia Caballero-Casero, Herbert Oberacher, Marja Lamoree, Annelaure Damont, François Fenaille, Jelle Vlaanderen, Jeroen Meijer, Martin Krauss, Denis Sarigiannis, Robert Barouki, Bruno Le Bizec, Jean-Philippe Antignac 04/2020
32 - Biomonitoring for occupational exposure to diisocyanates: a systematic review
Bernice Scholten, Laura Kenny, Radu-Corneliu Duca, Anjoeka Pronk, Tiina Santonen, Karen S Galea, Miranda Loh, Katriina Huumonen, Anne Sleeuwenhoek, Matteo Creta, Lode Godderis, Kate Jones 04/2020
33 - Relying on repeated biospecimens to reduce the effects of classical-type exposure measurement error in studies linking the exposome to health
Lydiane Agier, Rémy Slama, Xavier Basagaña 04/2020
34 - Towards Harmonized Biobanking for Biomonitoring: A Comparison of Human Biomonitoring-Related and Clinical Biorepositories
Dominik Lermen, Frederik Gwinner, Martina Bartel-Steinbach, Sabine C. Mueller, Jens K. Habermann, Matharoo-Ball Balwir, Elke Smits, Ana Virgolino, Ulrike Fiddicke, Marika Berglund, Agneta Åkesson, Anna Bergstrom, Karin Leander, Milena Horvat, Janja Snoj Tratnik, Manuel Posada de la Paz, Argelia Castaño Calvo, Marta Esteban López, Hagen von Briesen, Heiko Zimmermann and Marike Kolossa-Gehring 04/2020
35 - Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells
Katrin Kreuzer, Linda Böhmert, Deema Alhalabi, Thorsten Buhrke, Alfonso Lampen, Albert Braeuning 03/2020
36 - Comparison of polycyclic aromatic hydrocarbon metabolite concentrations in urine of mothers and their newborns
Katerina Urbancova, Darina Dvorakova, Tomas Gramblicka, Radim J. Sram, Jana Hajslova, Jana Pulkrabova 03/2020
37 - A European proposal for quality control and quality assurance of tandem mass spectral libraries
Herbert Oberacher, Michael Sasse, Jean-Philippe Antignac, Yann Guitton, Laurent Debrauwer, Emilien L. Jamin, Tobias Schulze, Martin Krauss, Adrian Covaci, Noelia Caballero-Casero, Kathleen Rousseau, Annelaure Damont, François Fenaille, Marja Lamoree, Emma L. Schymanski 03/2020
38 - Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis
Giorgia Adani, Tommaso Filippini, Lauren A. Wise, Thorhallur I. Halldorsson, Ludek Blaha and Marco Vinceti 03/2020
39 - Testing for thyroid hormone disruptors, a review of non-mammalian in vivo models
Stephan Couderq, Michelle Leemans, Jean-Baptiste Fini 03/2020
40 - Transcriptomic effect marker patterns of genotoxins – a comparative study with literature data
Katrin Kreuzer, Falko Frenzel, Alfonso Lampen, Albert Braeuning, Linda Böhmert 12/2019
41 - Pesticides with potential Thyroid Hormone-Disrupting Effects: A review of recent data
Michelle Leemans, Stephan Couderq, Barbara Demeneix and Jean-Baptiste Fini 12/2019
42 - Statement on advancing the assessment of chemical mixtures and their risks for human health and the environment
Elina Drakvik, Rolf Altenburger, Yasunobu Aoki, Thomas Backhause, Tina Bahadori, Robert Barouki, Werner Brack, Mark T.D. Cronin, Barbara Demeneix, Susanne HougaarD Bennekou, Jacobvan Klaveren, Carsten Kneuer, Marike Kolossa-Gehring, Erik Lebret, Leo Posthuma, Lena Reiber, Cynthia Rider, Joëlle Rüegg, Giuseppe Testa, Bart van der Burg, Hilkovan der Voet, A. Michael Warhurst, Bob van de Water, Kunihiko Yamazaki, Mattias Öberg, Åke Bergman 11/2019
43 - Deciphering adverse outcome pathway network linked to Bisphenol F using text mining and systems toxicology approaches
Marylène Rugard, Xavier Coumoul, Jean-Charles Carvaillo, Robert Barouki, Karine Audouze 10/2019
44 - Setting up a collaborative European human biological monitoring study on occupational exposure to hexavalent chromium
Tiina Santonen, Alessandro Alimonti, Beatrice Bocca, Radu Corneliu Duca, Karen S. Galea, Lode Godderis, Thomas Göen, Bruno Gomes. Ogier Hanser, Ivo Iavicoli, Beata Janasik, Kate Jones, Mirja Kiilunen, Holger M. Koch, Elizabeth Leese, Veruscka Leso, Henriqueta Louro, Sophie Ndaw, Simo P. Porras, Alain Robert, Flavia Ruggieri, Paul T.J. Scheepers, Maria J.Silva, Susana Viegas, Wojciech Wasowicz, Argelia Castano, Ovnair Sepai 07/2019
45 - A review of phthalate pharmacokinetics in human and rat: what factors drive phthalate distribution and partitioning?
Elena Domínguez-Romero, Martin Scheringer 06/2019
46 - Cadmium Exposure and Risk of Breast Cancer by Histological and Tumor Receptor Subtype in White Caucasian Women: A Hospital-Based Case-Control Study
Loreta Strumylaite, Rima Kregzdyte, Algirdas Bogusevicius, Lina Poskiene, Dale Baranauskiene and Darius Pranys 06/2019
47 - Cadmium Exposure and Risk of Breast Cancer by Histological and Tumor Receptor Subtype in White Caucasian Women: A Hospital-Based Case-Control Study
Loreta Strumylaite, Rima Kregzdyte, Algirdas Bogusevicius, Lina Poskiene, Dale Baranauskiene and Darius Pranys 06/2019
48 - A strategy to validate a selection of human effect biomarkers using adverseoutcome pathways: Proof of concept for phthalates and reproductive effects
Kirsten Baken, Nathalie Lambrechts, Greet Schoeters, et al. 05/2019
49 - Human biomonitoring in health risk assessment in Europe: Current practices and recommendations for the future
Henriqueta Louro, Tiina Santonen, et al. 05/2019
50 - Linking Bisphenol S to Adverse Outcome Pathways Using a Combined Text Mining and Systems Biology Approach
Jean-Charles Carvaillo, Robert Barouki, Xavier Coumoul and Karine Audouze 04/2019
51 - Linking past uses of legacy SVOCs with today's indoor levels and human exposure
Hale Demirtepe, Lisa Melymuk, Miriam L. Diamond, Lola Bajard, Šimon Vojta, Roman Prokeš, Ondřej Sáňka, Jana Klánová, Ľubica Palkovičová Murínová, Denisa Richterová, Vladimíra Rašplová, Tomáš Trnovec 04/2019
52 - Prioritization of hazards of novel flame retardants using the mechanistic toxicology information from ToxCast and Adverse Outcome Pathways
Lola Bajard, Lisa Melymuk and Ludek Blaha 02/2019
53 - Physiology-based toxicokinetic modeling in the frame of the European Human Biomonitoring Initiative
Sarigiannis, D.A., Karakitsios, S., Dominguez-Romero, E., Papadaki, K., Brochot, C., Kumar, V., Schumacher, M., Sy, M., Mielke, H., Greiner, M., Mengelers, M., Scheringer, M. 01/2019
54 - Annotating Non-targeted LC-HRMS/MS Data with Two Complementary Tandem Mass Spectral Libraries
Herbert Oberacher, Vera Reinstadler, Marco Kreidl, Michael A. Stravs, Juliane Hollender and Emma L. Schymanski 12/2018
55 - Development of Policy Relevant Human Biomonitoring Indicators for Chemical Exposure in the European Population
Jurgen Buekers et. al 09/2018
56 - Current EU research activities on combined exposure to multiple chemicals
Stephanie K. Bopp et. al, 08/2018
57 - Thyroid-disrupting chemicals and brain development: an update
Bilal B Mughal, Jean-Baptiste Fini, Barbara A Demeneix 04/2018
58 - Human biomonitoring in Israel: Recent results and lessons learned
Tamar Bermana et. al, 12/2017
59 - Special Issue „Human Biomonitoring 2016“
Gerda Schwedler et. al 03/2017
60 - Human biomonitoring as a tool to support chemicals regulation in the European Union
Catherine Ganzleben et. al, 01/2017

PEER REVIEWED ARTICLES WITH REFERENCE TO HBM4EU

1 - Towards a systematic use of effect biomarkers in population and occupational biomonitoring
Maryam Zare Jeddi, Nancy B.Hopf, Susana Viegas, Anna Bal Price, Alicia Paini, Christoph van Thriel, Emilio Benfenati, Sophie Ndaw, Jos Bessems, Peter A. Behnisch, Gabriele Leng, Radu-Corneliu Duca, Hans Verhagen, Francesco Cubadda, Lorraine Brennan, Imran Ali, Arthur David, Vicente Mustieles, Mariana F. Fernandez, Henriqueta Louro, Robert Pasanen-Kase 12/2020
2 - A call for urgent action to safeguard our planet and our health in line with the helsinki declaration
Jaana I. Halonena, Marina Erhola, Eeva Furman, Tari Haahtela, Pekka Jousilahti, Robert Barouki, Åke Bergman, Nils E. Billo, Richard Fuller, Andrew Haines, Manolis Kogevinas, Marike Kolossa-Gehring, Kinga Krauze, Timo Lanki, Joana Lobo Vicente, Peter Messerli, Mark Nieuwenhuijsen, Riikka Paloniemi, Annette Peters, Karl-Heinz Posch, Pekka Timonen, Roel Vermeulen, Suvi M. Virtanen, Jean Bousquet, Josep M.Antó 12/2020
3 - Bisphenol A shapes children's brain and behavior: towards an integrated neurotoxicity assessment including human data
Vicente Mustieles, Mariana F. Fernández 06/2020
4 - Deliverable 8.1 Description of the national programmes - a strategy to collect EU wide HBM data
Greet Schoeters (VITO) et al. 04/2018
5 - Deliverable 7.3 1st prioritisation Report on survey design: Study protocols, SOPs and Guidelines, tailored and transferred questionnaires for recruitment and sampling
Ulrike Fiddicke (UBA) et. al, 02/2018
6 - Additional Deliverable AD 8.2 Research plan for chromates study under HBM4EU
Sophie Ndaw (INRS) et. al, 01/2018
7 - Additional Deliverable 16.1 Screening methods inventory
Mariane Pourchet-Gellez (INRA) et. al, 12/2017
8 - Additional Deliverable 16.3 Direct effect based approaches applied to the screening of emerging substances
Marja Lamoree (VU-IVM) et. al, 12/2017
9 - Deliverable 10.2 Statistical Analysis Plan
Martine Vrijheid (ISGlobal) et. al, 12/2017
10 - Deliverable 12.2 Report on the optimal methodology for exposure reconstruction from HBM data
Milena Horvat (JSI) et. al, 12/2017
11 - Deliverable 16.1 Prioritised list of known emerging chemicals
Jelle Vlaanderen (IRAS) et. al, 12/2017
12 - Deliverable 5.3 Scoping paper on the development of an indicator on chemical exposure in the European population
Xenia Trier (EEA) et. al, 12/2017
13 - Deliverable 7.1 Report on ongoing activities and existing data and data gaps for the 1st prioritised substances including a list of metadata that can be uploaded in IPCheM
Ana Virgolino (FMUL) et. al, 12/2017
14 - Deliverable 7.2 Strategy and SOPs for human sample exchange, including ethical demands
Dominik Lermen (IBMT) et. al, 12/2017
15 - Additional Deliverable 15.3 HBM mixture database description and proposal statistical analysis plan
Jelle Vlaanderen (IRAS) et. al, 12/2017
16 - Additional Deliverable 5.1 A (phased) plan for action: how structurered multi-actor dialogues on human biomonitoring results can facilitate targeted policy action (generic canvas for HBM4EU)
Ann Crabbé (UAntwerpen) et. al, 12/2017
17 - Deliverable 5.2 1st substance-group specific derivation of EU-wide health-based guidance values
Petra Apel (UBA) et. al, 12/2017
18 - Deliverable 2.4 2018 Programme of training activities, materials and capacity building mechanisms
Paul T.J. Scheepers (RUMC) et. al, 12/2017
19 - Deliverable 5.1 Human biomonitoring in risk assessment: analysis of the current practice and 1st examples on the use of HBM in risk assessments of HBM4EU priority chemicals
Tiina Santonen (FIOH) et. al, 11/2017
20 - Deliverable 9.4 The Quality Assurance/Quality Control Scheme in the HBM4EU project
Thomas Göen (IPASUM) et. al, 11/2017
21 - Additional Deliverable 11.1 How can the results from BRIDGE Health be incorporated to the work of HBM4EU?
Madlen David (UBA) et. al, 10/2017
22 - Additional Deliverable 12.1 Database of exposure-related and ancillary data for priority substances
Alberto Gotti (IUSS) et. al, 10/2017
23 - Deliverable 9.3 Database of candidate laboratories for the 1st prioritisation round of substances
Octavio Pérez Luzardo (ULPGC) et. al, 10/2017
24 - Deliverable 2.3 2018 Strategy for the communication and dissemination of HBM4EU results
Catherine Ganzleben (EEA) et. al, 10/2017
25 - Deliverable 14.1 Criteria for prioritisation of biomarkers of effect
Nicolás Olea (UGR) et. al, 10/2017
26 - Additional Deliverable 11.2 Criteria for feasibility studies
Hanna Tolonen (THL) et. al, 09/2017
27 - Deliverable 1.8 Establishment of Stakeholder Forum and Advisory Board
Lena Reiber (UBA) et. al, 09/2017
28 - Deliverable 9.2 Prioritised list of biomarkers, matrices and analytical methods for the 1st prioritisation round of substances
Cathrine Thomsen (NIPH) et. al, 09/2017
29 - Deliverable 4.3 Prioritisation strategy and criteria
Jean-Nicholas Ormsby (ANSES) et. al, 08/2017
30 - Additional Deliverable 12.2 Roadmap for model PBTK/D model refinement and analysis for priority substances
Laurent Bodin (ANSES) et. al, 08/2017
31 - Additional Deliverable 12.1 Database of exposure-related and ancillary data for priority substances
Alberto GOTTI et. al, 07/2017
32 - Deliverable 10.1 Data Management Plan, July 2017
Sylvie Remy (VITO) et. al, 07/2017
33 - Annex to Deliverable 10.1 Data Policy, July 2017
Sylvie Remy (VITO) et. al, 07/2017
34 - Deliverable 4.2 Scoping documents on HBM4EU priority substances for 2018, June 2017
Greet Schoeters (VITO) et. al, 06/2017
35 - Additional deliverable 8.1 Report on access to occupational data
Tiina Santonen (FIOH) et. al, 06/2017
36 - Deliverable 13.1 Criteria for the selection of cohort studies, June 2017
Thorhallur Ingi Halldorsson (UI) et. al, 06/2017
37 - Deliverable 6.1 First set of key indicators for HBM4EU, June 2017
Hans Reynders et. al, 06/2017
38 - Deliverable 4.1 Template for the submission of rapid requests, May 2017
Jean-Nicolas Ormsby (ANSES) et. al, 05/2017
39 - Deliverable 9.1 Criteria for the prioritisation of biomarkers, April 2017
Loïc Rambaud (ANSP) et. al, 04/2017
40 - Deliverable 1.2 Establishment of the HBM4EU Governing Board
Ulrike Doyle (UBA) et. al, 03/2017
41 - Deliverable 2.1 HBM4EU Website, March 2017
Catherine Ganzleben and Derya Ay (EEA) 03/2017
42 - Deliverable 2.2 Strategy for the communication and disseminatoin of HBM4EU results, March 2017
Catherine Ganzleben (EEA) 03/2017
43 - Deliverable 1.2 Establishment of Governing Board, February 2017
Ulrike Doyle (UBA) et. al, 02/2017
44 - Grant Agreement, November 2016
Number: 733032 11/2016

Publications

What is HBM4EU?

Who does HBM4EU consist of?

What is human biomonitoring?

How will HBM4EU initiative work with human biomonitoring?

What are the main objectives of HBM4EU?